Second Independent Validation Study Initiated to Expand Prenatal Testing Window

Brisbane, Australia – January 2, 2026 – Ketim Technologies has commenced its second independent validation study of its signature protein panel for postpartum depression risk prediction.

The study introduces an additional pregnancy time point to assess:

• Stability of the identified biomarker signature
• Extension of the clinical testing window during routine antenatal care

The additional time point was informed by international market research conducted with mothers and clinicians across Australia, Europe, and the United States. Insights from these discussions identified optimal integration points within existing prenatal visits, enabling blood collection without increasing clinical burden.

This validation phase aims to strengthen the robustness of Ketim’s protein panel while enhancing real-world clinical feasibility and adoption.

In parallel, the company has submitted $4.5 million in competitive grant applications to support continued biomarker validation and regulatory progression.

“Our approach combines rigorous science, clinical practicality, and patient-centred design,” said Dr. Clarissa Yates, Founder and CEO. “Validation must not only confirm biological signal stability, but also align with how healthcare is delivered.”

Support from early investors, including AngelLoop, continues to enable the advancement of Ketim’s precision psychiatry platform as the company moves toward clinical and regulatory milestones.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au